Edgewise Therapeutics To Sell Muscular Dystrophy Business & Sevasemten For Up To $2.65 Bln
1/6 15:08
(RTTNews) - Edgewise Therapeutics, Inc. (EWTX), a biopharmaceutical company, Monday announced that it has agreed to sell its muscular dystrophy business and Sevasemten to Servier, an independent pharmaceutical group, for $1.55 billion in cash and up to $1.1 billion in additional...